Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AZN

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Benzinga

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

AstraZeneca plc (NASDAQ:AZN) announced on Tuesday that it will invest $50 billion in the United States by 2030.

Benzinga

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.

Benzinga

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension.

Benzinga

IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.

MarketBeat

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Global Stocks to Diversify Your Portfolio

Markets outside the United States don’t always move in sync with domestic trends, which means adding international stocks can help reduce volatility and spread risk. Thus, investors looking to diversify their portfolio can consider investing in fundamentally sound companies like SAP SE (SAP), AstraZeneca (AZN), and Alibaba Group (BABA) for…

StockNews.com

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Barchart

3 Blue-Chip Stocks for Long-Term Stability

With uncertainty looming over the stock market, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, Walmart (WMT), The Procter & Gamble (PG), and AstraZeneca (AZN), for stable results. Read more….

StockNews.com

How Is Bristol-Myers Squibb's Stock Performance Compared to Other General Drug Manufacturers?

Bristol-Myers Squibb has been lagging behind other drug manufacturers over the past three months, and analysts remain cautious about the stock's prospects.

Barchart

Is Pfizer Stock Underperforming the Nasdaq?

Pfizer has recently lagged the Nasdaq Composite, but analysts are optimistic about the stock’s prospects.

Barchart

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

Barchart

Is This Dividend Stock a Buy Now?

With a robust portfolio, this top pharma stock is a good mix of growth and income.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 A-Rated Pharma Stocks to Buy for Long-Term Growth

With surging medical needs, advances in precision medicine, and the adoption of generative AI, the pharmaceutical industry is thriving. Thus, it could be ideal to invest in quality pharma stocks Taro Pharmaceutical (TARO), AstraZeneca (AZN), and Merck (MRK) for long-term growth. These stocks are rated A (Strong Buy) in our…

Barchart

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

StockNews.com

3 Pharma Powerhouses for Long-Term Growth in 2024

Amid evolving technologies and strategic maneuvers, the pharma industry is set for paradigm-shifting growth, propelled by growing funding and drug discovery. Hence, fundamentally strong pharma stocks Collegium Pharmaceutical (COLL), AstraZeneca (AZN), and Merck & Co. (MRK) might be ideal buys this year for long-term growth. Read more….

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

Investors Business Daily

AstraZeneca Nose Dives On 'Thoroughly Underwhelming' Fourth-Quarter Results

AstraZeneca's quarterly results were "thoroughly underwhelming," an analyst said Thursday as he downgraded AZN stock to a sell rating.

StockNews.com

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com

3 Top-Rated Pharma Stock Picks to Consider in the New Year

The pharmaceutical industry is expected to grow rapidly due to rising global medical needs and technological advancements. With the industry expected to thrive in the coming years, it could be wise to buy Zoetis (ZTS), AstraZeneca (AZN) and Taro Pharmaceutical (TARO) for steady returns. Read more.

StockNews.com

3 Booming Pharma Stocks Making Waves in the Industry

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given this backdrop, it could be wise to buy Roche Holding (RHHBY), AstraZeneca (AZN) and Bristol-Myers Squibb (BMY), which look poised for steady returns. Keep reading.

Investors Business Daily

AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs

AZN stock popped after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.

StockNews.com

3 Pharma Stocks on the Rise - Buy Now

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. Thus, it would be prudent to buy pharma stocks, Sanofi (SNY), Johnson & Johnson (JNJ) and AstraZeneca PLC (AZN). Read on.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.